Synthesis of chitosan polyethylene glycol antibody complex for delivery of Imatinib in lung cancer cell lines

• Published in: Journal of biochemical and molecular toxicology Vol. 38; no. 8; pp. e23787 - n/a
• Main Authors: Kamali, Mehrdad, Jafari, Hanieh, Taati, Fatemeh, Mohammadnejad, Javad, Daemi, Amin
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.08.2024
• Subjects: A 549 cell line; A549 Cells; Antibodies; Antibodies, Monoclonal, Humanized - chemistry; Antibodies, Monoclonal, Humanized - pharmacology; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Cell cycle; Cell Line, Tumor; Cell viability; Chitosan; Chitosan - chemistry; chitosan nanoparticle; Drug Carriers - chemistry; Drug development; Flow cytometry; Fluid pressure; Humans; Imatinib; Imatinib Mesylate - pharmacology; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Nanoparticles; Non-small cell lung carcinoma; NSCLC treatment; Ph sensitive; Polyethylene glycol; Polyethylene Glycols - chemistry; Ramucirumab antibody; Small cell lung carcinoma; Surface charge; Tumor cell lines; Zeta potential; NSCLC treatment; Ph sensitive; Imatinib; A 549 cell line; chitosan nanoparticle; Ramucirumab antibody
• ISSN: 1095-6670; 1099-0461; 1099-0461
• DOI: 10.1002/jbt.23787

Lung cancer is known as the most common cancer. Although the Ramucirumab antibody is a second‐line treatment for lung cancer, the high interstitial fluid pressure limits the antibody's performance. In this way, Imatinib is a chemotherapeutic drug to reduce the interstitial fluid pressure. Up to now, unfortunately, both Ramucirumab and imatinib have not been reported in one nanosystem for cancer therapy. To fulfill this shortcoming, this paper aims to design a chitosan nanocarrier that loads imatinib and attaches to Ramucirumab for selective bonding to A549. Therefore, this paper aims to develop a polymeric nanosystem for non‐small cell lung cancer (NSCLC) treatment. In first, the chitosan polyethylene glycol nanoparticle is synthesized, loaded with imatinib, and then targeted using Ramucirumab. Afterwards, the CS‐PEG‐Ab‐Im by FTIR, TEM, DLS, zeta potential, and TGA techniques are characterized. The size of CS‐PEG‐Ab‐Im was 25–30 nm, its surface charge was 13.1 mV, and the shape of CS‐PEG‐Ab‐Im was nearly spherical and cylindrical. The therapeutic potential of CS‐PEG‐Ab‐Im was assessed using the A549 cell line. According to the obtained results, the cell viability was 48% after 48 h of treatment of A549 cells using the IC50 concentration of CS‐PEG‐Ab‐Im (100 nanomolar). Moreover, the apoptosis and cell cycle arrest percentages were increased by 3 and 6 times, respectively, as compared to free imatinib. Furthermore, the release rate of imatinib from CS‐PEG‐Ab‐Im in an acidic medium was 17% during 1 h, indicating five times the imatinib release in the natural medium. Eventually, the result of flow cytometry indicates the more apoptotic effect of nanosystem to free imatinib and CS‐PEG‐Ab. Besides, cell arresting result exhibits the CS‐PEG‐Ab‐Im and causes cell arrested at G1 by %8.17. Thus, it can be concluded that CS‐PEG‐Ab‐Im can be an ideal nanosystem in NSCLC treatment. All obtained results accommodate each other and reveal that CS‐PEG‐Ab‐Im can be an ideal nanosystem in non‐small cell lung cancer (NSCLC) treatment.